Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F14 (sustained-release celecoxib) for postoperative pain after total knee replacement
NCT05603832Phase 3Completed
- Sponsor
- Arthritis Innovation Corporation
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Injectable Hydrogels, Device-based Delivery, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of F14 in postoperative pain, sponsored by Arthritis Innovation Corporation. Started Nov 2022; status: completed.
02
Drugs
F14
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05603832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603832.